Media coverage about Adamas Pharmaceuticals (NASDAQ:ADMS) has trended somewhat positive on Monday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.1846960357629 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s scoring:

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 21.01% during trading on Monday, reaching $23.61. 5,220,021 shares of the company’s stock were exchanged. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $24.55. The stock’s market cap is $531.56 million. The company has a 50 day moving average of $20.66 and a 200 day moving average of $17.95.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. The business’s quarterly revenue was down 90.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.78) EPS. Equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.77) EPS for the current year.

Several brokerages recently commented on ADMS. Evercore ISI began coverage on shares of Adamas Pharmaceuticals in a report on Monday. They set an “outperform” rating on the stock. Mizuho reiterated a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. BidaskClub downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. Finally, Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $39.50.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Adamas Pharmaceuticals (ADMS) Share Price” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/10/30/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-adamas-pharmaceuticals-adms-share-price.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.